STRATA Skin Sciences’ Commitment to Patient Care
STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a dedicated leader in medical technology for dermatological treatments, is making great strides in the field of skin health. With a focus on innovative solutions, the company is working diligently with the Centers for Medicare & Medicaid Services (CMS) to improve access to essential treatments for patients suffering from chronic skin conditions.
Expanded Reimbursement for XTRAC® Excimer Laser Treatment
STRATA's efforts have led to significant developments regarding the reimbursement process for its XTRAC® excimer laser treatment. With the recent approval by the American Medical Association’s CPT Editorial Panel, reimbursement eligibility has been expanded to include a wider range of skin conditions, including vitiligo, atopic dermatitis, and alopecia areata, alongside psoriasis. This monumental decision, effective January 1, 2027, opens the door for a greater number of patients, potentially tripling the addressable market to accommodate over 30 million individuals seeking effective and safe treatment options.
Why This Matters to Patients
Dr. Dolev Rafaeli, President and CEO of STRATA, emphasizes that this initiative is about more than financial benefits; it's about improving health outcomes for millions. "Securing temporary CMS codes ahead of the anticipated changes in 2027 will enable us to bring our non-drug treatment options to a broader patient population, enhancing the overall experience and quality of care received by patients with chronic conditions,” he states. This proactive approach highlights STRATA's commitment to patient welfare and effective treatment solutions.
Promising Results from Recent Studies
The efficacy of the XTRAC laser is backed by peer-reviewed studies affirming its success in treating vitiligo. A multicenter randomized controlled trial demonstrated notable improvements when using the 308-nm excimer laser paired with Janus kinase (JAK) inhibitors. This combination led to outstanding results, with patients achieving re-pigmentation rates of up to 100% along with high stability in their responses. Such findings solidify XTRAC’s position as a favorable drug-free therapy amidst the rise of complex treatment options and showcase the positive impact it can deliver for those affected.
Continuous Improvement through Research
Ongoing clinical research supports the safety and efficacy of combining laser therapy with immune-modulating drugs. STRATA remains dedicated to identifying additional uses for excimer laser treatment to further enhance patient outcomes. The encouraging outcomes from these studies not only validate STRATA's technology but also reinforce its pivotal role in advancing dermatological care in modern medicine.
Legal Matters and Company Integrity
In addition to expanding treatment access, STRATA is concurrently addressing legal issues relating to false advertising within the dermatological technology sector. The company has made progress in its lawsuit against LaserOptek America, with the Federal District Court agreeing to include the parent company, LaserOptek Korea, as a defendant. This legal victory underscores STRATA's determination to uphold its reputation and ensure accountability for misleading practices that undermine patient trust.
Landmark Legal Developments
The ongoing litigation, originally filed due to alleged false marketing claims about Pallas lasers, aims to protect both practitioners and patients from unnecessary risks associated with non-reimbursable treatment claims. STRATA is committed to transforming this challenging situation into an opportunity for positive change and accountability within the industry.
Why STRATA Stands Out
What sets STRATA apart is its unique approach to partnering with medical practices. Rather than traditional purchase models, STRATA offers a Partnership Program that allows cost-effective access to advanced treatment technologies, training, and support. This method not only improves the accessibility for healthcare practitioners but also enhances the overall patient experience.
Innovative Medical Technology for Better Healthcare
STRATA’s portfolio of products includes the XTRAC® excimer laser and other therapeutic solutions designed to address various dermatological conditions effectively. The company’s mission is to deliver innovative therapies that prioritize patient safety and success while fostering an environment of expert collaboration between practitioners and patients.
Frequently Asked Questions
What is the purpose of the expanded reimbursement for XTRAC treatment?
The expansion aims to increase patient access to XTRAC treatment for various chronic inflammatory skin conditions, thus tripling the potential patient base.
How does STRATA's Partnership Program benefit medical practices?
The program provides practices with a fee-per-treatment model, comprehensive training, and ongoing support, enhancing patient care without prohibitive upfront costs.
What recent studies support the efficacy of Excimer Laser therapy?
Recent studies have confirmed the safety and effectiveness of combining Excimer Laser therapy with JAK inhibitors for treating vitiligo and related skin conditions.
What legal challenges is STRATA currently facing?
STRATA is involved in a lawsuit against LaserOptek America and its parent company, addressing claims of false advertising and ensuring compliance in marketing practices.
How can patients learn more about STRATA's treatments?
Patients can consult with their healthcare providers about treatment options or visit STRATA's official website for more information about available therapies.
